F. Melo Cruz

Statistics

Publications

Citations

161

H-Index

Active since

2016

Affiliations

Instituto Brasileiro de Controle do Câncer(Current)

The University of Texas MD Anderson Cancer Center

Novartis (United States)

F. Melo Cruz is an author at Instituto Brasileiro de Controle do Câncer specializing in hormone receptor-positive breast cancer therapy, breast oncology, and her2-positive breast cancer.

Publications per year

2016–2024

Publications

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Gabriel N. Hortobágyi, Joohyuk Sohn, F. Melo Cruz et al. · Annals of Oncology · 2024 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martín Jiménez, Elgene Lim, Amit Bardia et al. · Annals of Oncology · 2022 · 58 citations · Full text

Medicine, Endocrinology, Oncology +16

BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)

Melanie Royce, Christian Villanueva, Mustafa Özgüroğlu et al. · Annals of Oncology · 2016 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17

1–3 of 3